Search
for
Sort by
Research 511–540 of 524
- Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023)
- An Updated in the Management of Alopecia Areata
- Hair Growth Effect of DN106212 in C57BL/6 Mouse and Its Network Pharmacological Mechanism of Action
- The potential of regulatory T cell-based therapies for alopecia areata
- Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
- Alopecia Areata in Latin America: Where are We and Where are We Going?
- Baricitinib Attenuates IFN-γ and Polyinosinic:polycytidylic Acid‒Induced Mitochondrial Damage and Inflammasome Activation in Human Keratinocytes
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- DataSheet1_Vitiligo: An Autoimmune Skin Disease and its Immunomodulatory Therapeutic Intervention.PDF
- Updates From 2021 Virtual Dermatology Nurses' Association Convention
- Proceedings of the Ninth World Congress for Hair Research (2015)
- European expert consensus statement on the systemic treatment of alopecia areata
- Update From Dermatology Nurses’ Association Convention 2025
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- JAK inhibitors in dermatology: The promise of a new drug class
- Emerging Topical and Systemic JAK Inhibitors in Dermatology
- Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Hair Growth Effect of Emulsion Extracted Brevilin A, a JAK3 Inhibitor, from Centipeda minima
- Under Development JAK Inhibitors for Dermatologic Diseases
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- 455 Beyond Immunity: TEC and JAK3 Kinase Activation in Melanocytes Drives Inflammation in Vitiligo
- Environmental Modulation of JAK3-Mediated Immune Dysregulation in Alopecia Areata
- 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
- 0935 Unravelling the role of JAK3/TEC kinase signalling with ritlecitinib in alopecia areata lesional skin and alopecia areata-induced human hair follicles ex vivo
- CS12192 Reverses Alopecia Areata by Selectively Targeting JAK3/JAK1/TBK1.